Skip to main content

Table 2 Kaplan-Meier mean and median ages at first use of NV in patients with DMD

From: Influence of β2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy

 

Mean Age

Median Age

Estimate (yrs)

SE

95% CI

Estimate (yrs)

SE

95% CI

Arg16

25.91*

1.31

23.35–28.49

28.30*

4.14

20.19–36.41

Gly16

21.80

0.59

20.86–23.42

22.17

0.40

21.38–22.96

Overall

22.71

0.62

21.49–23.93

22.48

0.39

21.72–23.24

  1. SE standard error, CI confidence interval, Arg16: patients who were homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n = 147). *Significant difference in mean or median age at first use of NV between genotype groups, P < 0.05